Vukojevic, J., Milavić, M., Perović, D., Ilić, S., Čilić, A. Z., Đuran, N., Štrbe, S., Zoričić, Z., Filipčić, I., Brečić, P., Seiverth, S., & Sikirić, P. (2022). Pentadecapeptide BPC 157 and the central nervous system. Neural Regeneration Research/Neural Regeneration Research , 17 (3), 482. https://doi.org/10.4103/1673-5374.320969 Sikiric, P., Gojkovic, S., Krezic, I., Smoday, I. M., Kalogjera, L., Zizek, H., Oroz, K., Vranes, H., Vukovic, V., Labidi, M., Strbe, S., Oreskovic, L. B., Sever, M., Tepes, M., Knezevic, M., Barisic, I., Blagaic, V., Vlainic, J., Dobric, I., . . . Seiwerth, S. (2023). Stable gastric pentadecapeptide BPC 157 may recover Brain–Gut axis and Gut–Brain axis function. Pharmaceuticals , 16 (5), 676. https://doi.org/10.3390/ph16050676 Seiwerth, S., Milavic, M., Vukojevic, J., Gojkovic, S., Krezic, I., Vuletic, L. B., Pavlov, K. H., Petrovic, A., Sikiric, S., Vranes, H., Prtoric, A., Zizek, H., Durasin, T., Dobric, I., Staresinic, M., Strbe, S., Knezevic, M., Sola, M., Kokot, A., . . . Sikiric, P. (2021). Stable gastric pentadecapeptide BPC 157 and wound healing. Frontiers in Pharmacology , 12 . https://doi.org/10.3389/fphar.2021.627533

Cao, J., Belousoff, M. J., Johnson, R. M., Keov, P., Mariam, Z., Deganutti, G., Christopoulos, G., Hick, C. A., Reedtz-Runge, S., Glendorf, T., Ballarín-González, B., Raun, K., Bayly-Jones, C., Wootten, D., & Sexton, P. M. (2025). Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nature Communications, 16, Article 3389. https://doi.org/10.1038/s41467-025-58680-y Chavda, V. P., Ajabiya, J., Teli, D., Bojarska, J., & Apostolopoulos, V. (2022). GLP-2-T, a new era of dual-targeted treatment for diabetes and obesity: A mini review. Molecules, 27(13), 4315. https://doi.org/10.3390/molecules27134315 D’Ascanio, A. M., Mullally, J. A., & Frishman, W. H. (2024). Cagrilintide: A long-acting amylin analog for the treatment of obesity. Cardiology in Review, 32(1), 83–90. https://doi.org/10.1097/CRD.0000000000000513 Kruse, T., Hansen, J. L., Dahl, K., Schäffer, L., Sensfuss, U., Poulsen, C., Schlein, M., Hansen, A. M. K., Jeppesen, C. B., de la Cour, C. D., Clausen, T. R., Johansson, E., Fulle, S., Skyggebjerg, R. B., & Raun, K. (2021). Development of cagrilintide, a long-acting amylin analogue. Journal of Medicinal Chemistry, 64(17), 11183–11194. https://doi.org/10.1021/acs.jmedchem.1c00565 Min, T., & Bain, S. C. (2020). The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: The SURPASS clinical trials. Diabetes Therapy, 11(9), 1941–1957. https://doi.org/10.1007/s13300-020-00981-0

Information for 1415456-99-3/2023788-19-2 Blend

Order 1415456-99-3/2023788-19-2 Blend

Research Certificates of Analysis

1415456-99-3/2023788-19-2 Blend<br>11.27mg CAS #: 2023788-19-2 / 1.11mg CAS #: 1415456-99-3<br>Task #44542<br>Batch HCT-0003<br>06/27/2024

1415456-99-3/2023788-19-2 Blend
11.27mg CAS #: 2023788-19-2 / 1.11mg CAS #: 1415456-99-3
Task #44542
Batch HCT-0003
06/27/2024

Product Usage

This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.

Heat Up Your Summer Research! Use Code SUMMERTIME40 for 40% Off all Research Products.

Information for 1415456-99-3/2023788-19-2 Blend

Research Certificates of Analysis

Product Usage

Related Products

Welcome!